Green Lifescience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Green Lifescience makes the chemical building blocks, known as active pharmaceutical ingredients and intermediates, that drug companies use to manufacture finished medicines, as well as specialty chemicals for crop protection and electronic materials.
It supplies these products to global pharmaceutical companies and materials firms, sitting upstream in the supply chain as a contract manufacturer (a company that produces to a customer's specification). Listed on KOSDAQ, Korea's tech and small-cap board, the company is expanding its product portfolio beyond pharmaceutical ingredients into precision chemicals for circuit boards and QLED display materials.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates contract manufacturing using specialized capabilities including large-scale reactor equipment, phosgene reaction processes, and hydrogenation reaction technology, capabilities it explicitly highlights as a core strategic business.
Green Lifescience in five facts
What does Green Lifescience do?
Green Lifescience makes the chemical building blocks, known as active pharmaceutical ingredients and intermediates, that drug companies use to manufacture finished medicines, as well as specialty chemicals for crop protection and electronic materials.
Where is Green Lifescience listed and in which sector?
Green Lifescience (Korean name: 그린생명과학) trades under KRX code 114450 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Green Lifescience?
Its market capitalisation was US$34.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Green Lifescience's latest annual revenue and operating profit?
For fiscal year 2025, Green Lifescience reported revenue of US$30.4M, operating profit of US$154.2K and net income of US$83.1K, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 62.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of largest shareholder
Green Lifescience Co., Ltd. reports that its largest shareholder changed on July 22, 2026 from Gwanak Trading Co., Ltd. and two others (5,361,543 shares, 26.81%) to Green Chemical Co., Ltd. and two others (5,392,782 shares, 26.96%), following open-market purchases of US$41.8K by a related party to strengthen control; no change in management is planned.
Ownership change · Jul 22 - [Amended] Supply contract signed
Green Lifescience updated a previously disclosed supply contract with UPL Limited, now worth US$6.61M, about 41.18% of its recent annual revenue, running through Jun 2026.
Supply contract · Jun 30 - Treasury share disposal: results reportTreasury Shares · Jun 4
- Supply contract signed
Green Lifescience disclosed a supply contract with Green Chemical, worth US$6.75M, about 24.91% of its recent annual revenue, running through Dec 2026.
Supply contract · May 13 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Green Lifescience updated its previously filed separate results for FY2025: revenue of US$27.2M (+62.3% year on year), operating profit of US$138K (−45.8% year on year) and net income of US$74.2K (−92.9% year on year).
Earnings · Mar 18 · 2 versions - Supply contract signed
Green Lifescience disclosed a supply contract with Green Chemical, worth US$9.42M, about 56.43% of its recent annual revenue, running through Dec 2026.
Supply contract · Mar 17 - [Amended] Material event report (treasury share disposal)
Green Lifescience updated a disclosed plan to sell treasury shares worth US$302K, about 1.0% of its market value.
Treasury Shares · Mar 4 · 2 versions